| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 12/19/2001 | EP1163213A1 Hydroxamic and carboxylic acid derivatives |
| 12/19/2001 | EP1163208A2 Caspase inhibitors and uses thereof |
| 12/19/2001 | EP1163009A1 Gel-microemulsion formulations |
| 12/19/2001 | EP1163008A1 Use of trehalose for stabilising a liquid vaccine |
| 12/19/2001 | EP1163002A2 Polycationic carbohydrates as immunostimulants in vaccines |
| 12/19/2001 | EP1163001A2 Vaccine composition |
| 12/19/2001 | EP1163000A2 Vaccine against antigens from bacteriae |
| 12/19/2001 | EP1162999A2 Vaccine against Streptococcus pneumoniae |
| 12/19/2001 | EP1162998A2 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 12/19/2001 | EP1162997A2 Staphylococcus antigen and vaccine |
| 12/19/2001 | EP1162994A1 A means for the prophylactic and therapeutic treatment of streptococcal infections |
| 12/19/2001 | EP1162992A2 Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use |
| 12/19/2001 | EP1162971A2 Use of a non-nucleoside reverse transcriptase inhibitor (nni) for the treatment of hiv infection |
| 12/19/2001 | EP1162970A2 Anti-inflammatory uses of manzamines |
| 12/19/2001 | EP1162953A2 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances |
| 12/19/2001 | EP1162945A1 Particle based vaccine composition |
| 12/19/2001 | EP1162883A1 Oral anti-odor compositions |
| 12/19/2001 | EP1086109A4 Process for preparing crystalline salts of amoxycillin |
| 12/19/2001 | EP0813520B1 Arylsulfonylamino hydroxamic acid derivatives |
| 12/19/2001 | EP0751785B2 Combinations of thrombolytically active proteins and anticoagulants, and uses thereof |
| 12/19/2001 | EP0746624B1 Vector for liver-specific gene expression |
| 12/19/2001 | EP0728001B1 Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections |
| 12/19/2001 | EP0535021B1 Association between a human immunodeficiency virus-related retrovirus and sjogren's syndrome |
| 12/19/2001 | CN1327450A Regulatory/unfolding peptides of ezrin |
| 12/19/2001 | CN1327388A Modified antibodies of induced anti-idiotype reaction enhancement |
| 12/19/2001 | CN1327385A Anti-bacterial medicinal compositions |
| 12/19/2001 | CN1327382A Improved formulation for topical non-invasive application in vivo |
| 12/19/2001 | CN1326939A Producing influenza killed vaccine by sepharose 4FF column chromatography technology |
| 12/19/2001 | CN1326783A New indication of human interleukin-2 and antituberculotic combination medicine |
| 12/19/2001 | CN1326770A Plant health drink for relieving cough and diminishing inflammation |
| 12/19/2001 | CN1326758A Medicine for curing shaoyang disease and its preparing method |
| 12/19/2001 | CN1326756A Transdermal administration preparation of traditional Chinese medicine compound ginseng and safflower ointment and its preparing method |
| 12/19/2001 | CN1326755A Life prolonging detoxicating powder |
| 12/19/2001 | CN1326751A Paste made of Euphorbia lunulata bunge |
| 12/19/2001 | CN1326743A Process for preparing 1,3-oxygen-sulphur cyclopentane nucleotide like medicine composition |
| 12/19/2001 | CN1326742A Quick recovery ointment for tinea skin |
| 12/19/2001 | CN1326740A Minocycline vaginal solution agent |
| 12/19/2001 | CN1326738A Minocycline vaginal effervescent tablets |
| 12/19/2001 | CN1326737A External use medicine for curing sexual disease and its preparing process |
| 12/19/2001 | CN1326735A Yangru ofloxacin and its production process |
| 12/18/2001 | US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) |
| 12/18/2001 | US6331565 Inhibit virus dna replication and antigen expression |
| 12/18/2001 | US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors |
| 12/18/2001 | US6331540 Enhancing stability of aqueous pharmaceutical composition containing xanthan gum and fluoroquinolone antibiotic drug by adding water-soluble calcium salt |
| 12/18/2001 | US6331539 Sulfonamide and sulfamide substituted imidazoquinolines |
| 12/18/2001 | US6331522 Antibacterial and antifungal peptide |
| 12/18/2001 | US6331521 Beta-1,3-glucan synthase inhibitors; pneumocystis pneumonia infection treatment; fungicides |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | US6331425 Nucleotide sequences coding enzymatic polypeptide; for use in the diagnosis and treatment of cancer, meningitis and urogenital disorders; for sequencing preferential oligosaccharides |
| 12/18/2001 | US6331417 Determine amount of target nucleotide sequences in sample; mix sample with control sequences, incubate with nucleotide sequences, perform nucleotide sequence amplification, calculate amount of control and target sequences |
| 12/18/2001 | US6331411 TopA |
| 12/18/2001 | US6331410 Polynucleotides encoding a novel pyrR homolog |
| 12/18/2001 | US6331404 HIV envelope polypeptides |
| 12/18/2001 | US6331316 2',3'-dideoxyinosine and methacrylic acid copolymer core; resistance to disintegration; drug release properties |
| 12/18/2001 | CA2085589C Benzoquinazoline compounds |
| 12/18/2001 | CA2083143C Process for the preparation of 7.alpha.-alkoxycephem derivatives |
| 12/18/2001 | CA2074215C Improved oral dosing formulations of dideoxy purine nucleosides |
| 12/13/2001 | WO2001094952A2 Methods and compositions for modulating oxidized ldl transport |
| 12/13/2001 | WO2001094645A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094612A2 Method for identifying medically valuable active substances |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094369A2 Heterocycle derivatives and methods of use for treating anthrax infection |
| 12/13/2001 | WO2001094368A1 2-aminocarbonyl-9h-purine derivatives |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094348A1 Antiviral agents |
| 12/13/2001 | WO2001094342A1 Novel oxazolidinone derivatives and a process for the preparation thereof |
| 12/13/2001 | WO2001094300A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/13/2001 | WO2001093913A2 T cell receptor fusions and conjugates and methods of use thereof |
| 12/13/2001 | WO2001093906A1 Adjuvant composition comprising fha protein or fragment of fha protein in free form |
| 12/13/2001 | WO2001093904A1 Method of treating gastrointestinal diseases associated with species of genus clostridium |
| 12/13/2001 | WO2001093898A1 Methods of treating viral diseases with il-18 and il-18 combinations |
| 12/13/2001 | WO2001093891A1 Non-antibacterial tetracycline as anti-fungal agents |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093881A1 Immunological substance containing enteroabsorbable anti-inflammatory factor and application thereof |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093872A1 Use of organophosphorous hydroxamic acid derivatives for producing medicaments |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093866A1 Compounds with anti-hsv activity |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093846A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 12/13/2001 | WO2001093843A2 Benzoic acid esters having antiplasmid effect |
| 12/13/2001 | WO2001093829A2 Powder compositions |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001070225A3 Oxazolidinone tablet formulation |
| 12/13/2001 | WO2001051603A3 Pharmaceutical composition and method of using the same |
| 12/13/2001 | WO2001046408A3 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001044200A3 Selective neurokinin antagonists |
| 12/13/2001 | WO2001040241A3 6-o-alkyl-2-nor-2-substituted ketolide derivatives |
| 12/13/2001 | WO2001037881A3 Gene therapy of hiv-positive patients by the expression of membrane-anchored gp41 peptides |
| 12/13/2001 | WO2001035899A3 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 12/13/2001 | WO2001027136A3 Peptides which stimulate the immune response and tissue regeneration |
| 12/13/2001 | WO2001026682A3 Modified plant viruses and methods of use thereof |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000029008A9 Hiv-specific t-cell induction |